



CONTINUING MEDICAL EDUCATION

Reducing Cardiometabolic Risk for Patients with Type 2 Diabetes or Prediabetes with the CINEMA Program – An Update on a Novel, Integrated, Patient-Centered Program in the UH Health System – 65014-65006

Date: June 25, 2024 Time: 12:15 PM-1:00 PM

Online

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

1 Describe how continuous glucose monitoring may benefit patients with cardiovascular-kidney-metabolic (CKM) syndrome independent of insulin use.

2 Identify 2 new studies of cardiometabolic medications that expand benefits to chronic kidney disease and obstructive sleep apnea outcomes in patients with CKM syndrome.

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 0.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
George Topalsky, MD	Other Planning Committee Member	Nothing to disclose - 06/13/2024
Sona Kirpekar, MD	Course Director	Nothing to disclose - 02/29/2024
Michael Adornetto, DO, MBA	Other Planning Committee Member	Nothing to disclose - 02/27/2024
Crystal Mosca, MD	Other Planning Committee Member	Nothing to disclose - 05/10/2024
Ian J Neeland, MD	Faculty	Consulting Fee-Boehringer





		Ingelheim Consulting Fee-Eli Lilly and Co. Consulting Fee-Novo Nordisk Consulting Fee-Nestle Health Sciences Consulting Fee-Bayer Corporation - 02/26/2024
Sandra Clifton, 0	Other Planning Committee Member	Nothing to disclose - 03/01/2024